Congenital Adrenal Hyperplasia

Nephrology·MeSH: Adrenal Hyperplasia, Congenital

Prevalence

5.0 / 100K

8 drugs in development·5 companies·14 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
hydrocortisone	Impax Laboratories, LLC (IPXL)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(2)

Drug	Company
chronocort	NEUROCRINE BIOSCIENCES INC (NBIX)
crinecerfont	NEUROCRINE BIOSCIENCES INC (NBIX)

Phase 2(3)

Drug	Company
atumelnant	Crinetics Pharmaceuticals, Inc. (CRNX)
spr001	SPRUCE BIOSCIENCES, INC. (SPRB)
tildacerfont	SPRUCE BIOSCIENCES, INC. (SPRB)

Preclinical(1)

Drug	Company
spr202	SPRUCE BIOSCIENCES, INC. (SPRB)

BioSniper tracks 8 drugs in development for Congenital Adrenal Hyperplasia across 5 companies.

There are 14 clinical trials targeting Congenital Adrenal Hyperplasia tracked by BioSniper.

The estimated prevalence of Congenital Adrenal Hyperplasia is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.